Psy14 Economic Impact of Potential Drug-Drug Interactions Among Patients Taking Opioid Analgesics

Abstract

OBJECTIVES:In common with other chronic conditions, fibromyalgia syndrome (FMS) adversely affects Health-Related Quality of Life (HRQoL) and functional status. FMS often results in disability and profoundly affects the performance of daily activities, both at work and at home. This study was conducted to assess the patient-level burden among subjects with FMS. METHODS: A prospective, observational study was carried out on FMS patients from 44 medical centers throughout Korea. HRQoL scores were obtained using the Short Form (SF)-36 Health Survey. To estimate recent 3 month healthcare and non-healthcare cost, and productivity loss of FMS patients, participants completed a standardized questionnaire. Cost items mainly included healthcare cost such as outpatient, pharmacy, inpatient, and oriental medicine; non-healthcare cost such as traffic expenses, nursing cost, complementary and alternative medicine. Cost included insurance-covered cost as well as patient's out-of-pocket expenses during 3 months. To estimate productivity loss due to morbidity, days away from work due to FMS were also investigated. RESULTS: Among 1,040 FMS patients who completed the questionnaire, female was 92% (nϭ957). Approximately 45.7% of patients had rheumatic diseases. HRQoL physical component mean scores were determined as 35.9Ϯ7.5, and mental component mean scores were determined as 34.6Ϯ12.6. Number of out-patient visits within 3 months was 4.0Ϯ6.5. Total costs over 3 months were 1,609Ϯ2,055 USD. Within 3 months, 23.4% and 91.2% of patients with FMS had been away from work and reported the decreased work productivity, respectively. In the preceding 3 months, FMS patients missed 20 (SDϭ28.1) days of work, left work early an average of 28 (SDϭ31.0) days, and accomplished less at work an average of 65 (SDϭ30.0) days. CONCLUSIONS: Our results suggested that the patient-level burden among FMS sufferers in Korea is significant, evidenced by negative effect on health-related quality of life, health resource use and work/activity limitations.

Complex analysis of the personalized pharmacotherapy in the management of COVID-19 patients and suggestions for applications of predictive, preventive, and personalized medicine attitude

“…We also provide recommendations in the "Conclusions and Recommendations" section based on our results, which can facilitate translation of our results into routine hospital procedures or primary health care, offices of general practitioners. Moreover, PPPM-attitude-based COVID-19 management can reduce the possibility of additional interventions for serious DDIs or unfavourable alleles in actional pharmacogene-generated toxicity, thus improving the cost-benefit of COVID-19 treatment [44,45].…”